Medline Raises Sales Outlook To 10.0% To 10.5% And Adds $1 Billion Buyback As Nine-Month Profit Falls 28.8%
The med-surg supplier lifted its organic sales forecast and held its profit range, while nine-month net income fell to $696 million.
Medline, which makes and distributes medical-surgical supplies to hospitals and other care sites, raised its full-year organic sales growth forecast to 10.0% to 10.5%, from 9.0% to 10.0%, in a third-quarter earnings release on Wednesday. Quarterly net income slipped 1.2% to $318 million, and the company disclosed a $1 billion share repurchase program approved by its board in October.
Sales up, profit down
Third-quarter net sales rose 10.4% to $7.9 billion from $7.1 billion a year earlier, with organic sales up 10.5%. The company credited existing-customer growth and the rollout of 2025 signings. Net income fell from $322 million, which Medline tied to inventory costs from inflation, higher operating expenses and customer mix.
Adjusted EBITDA, the company's adjusted operating profit measure, rose 11.8% to $960 million from $859 million. Diluted earnings per share were $0.22, and adjusted diluted earnings per share were $0.44.
Over nine months, net sales rose 10.9% to $22.9 billion, but net income dropped 28.8% to $696 million from $977 million. Medline cited higher operating expenses and net losses of $316 million from the fire at its Tracy, California, distribution center. Nine-month adjusted EBITDA rose 5.0% to $2.8 billion.
Tariff refunds pad the numbers
After the Supreme Court's February 2026 ruling that IEEPA tariffs were unauthorized, Medline recognized $81 million of net tariff refund benefits in the quarter and $324 million over nine months. The nine-month figure reflects $402 million of refunds, partly offset by a $78 million cut to net sales for accrued customer repayments. All of it sits in the Medline Brand segment.
The reaffirmed adjusted EBITDA outlook of $3.3 billion to $3.4 billion excludes those refunds.
Medline Brand, which sells the company's own products, grew quarterly sales 6.6% to $3.6 billion. Supply Chain Solutions, which sells other suppliers' products and offers logistics services, grew 13.9% to $4.2 billion, but its adjusted EBITDA fell 10.2% to $184 million.
Cash, debt and the buyback
Free cash flow for the first nine months was $1.8 billion, from $2.2 billion of operating cash flow less $348 million of capital spending, mostly on warehouse automation, new distribution centers and kitting capacity. Medline also prepaid $750 million of its 2033 term loan.
The repurchase program covers up to $1 billion of Class A stock or units of Medline Holdings, LP. The company is not obligated to buy any set amount, and it can change or end the program at any time.
CEO Jim Boyle called it "another strong quarter," and management hosts an investor call at 9:30 a.m. ET on Wednesday.
Net debt stood at $9.1 billion at the end of the quarter, or 2.5 times trailing adjusted EBITDA, according to the company's reconciliation.
Sources
- 8-K Filing — Medline Inc. (MDLN) — SEC EDGAR
- Exhibit ex9913q26pressrelease.htm — Medline Inc. 8-K exhibit — SEC EDGAR